Identification

Name
Lamotrigine
Accession Number
DB00555  (APRD00570)
Type
Small Molecule
Groups
Approved, Investigational
Description

Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class used in the treatment of epilepsy and bipolar disorder. For epilepsy it is used to treat partial seizures, primary and secondary tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. Lamotrigine also acts as a mood stabilizer. It is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. In the US, lamotrigine is available as oral tablets under the market name Lamictal. Chemically unrelated to other anticonvulsants, lamotrigine has relatively few side-effects and does not require blood monitoring. While lamotrigine is primarily indicated for epilepsy and bipolar disorders, there is evidence that it could have some clinical efficacy in some neuropathic pain states. Lamotrigine is also used as an off-label drug in treating other neurologic and psychiatric pathologies like borderline personality disorder [6]. The exact mechanism of action of lamotrigine is not fully elucidated, as it may have multiple cellular actions that contribute to its broad clinical efficacy.

Structure
Thumb
Synonyms
  • 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
  • Lamotrigina
  • Lamotrigine
  • Lamotriginum
External IDs
BW 430 C / BW 430C / BW-430C / GW 273293
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LamictalTablet150 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-02-292017-11-07Us
LamictalTablet100 mg/1OralGlaxosmithkline Inc1995-01-17Not applicableUs00173 0642 55 nlmimage10 c518e287
LamictalTablet150 mg/1OralRebel Distributors1995-01-17Not applicableUs00173 0643 60 nlmimage10 f118f8a7
LamictalTablet100 mg/1OralPd Rx Pharmaceuticals, Inc.1995-01-17Not applicableUs
LamictalTablet2 mgOralGlaxosmithkline Inc2001-09-13Not applicableCanada
LamictalTablet100 mgOralGlaxosmithkline Inc1995-12-31Not applicableCanada
LamictalTablet100 mg/1OralPhysicians Total Care, Inc.2008-05-09Not applicableUs
LamictalTablet200 mg/1OralGlaxosmithkline Inc1995-01-18Not applicableUs00173 0644 60 nlmimage10 b218d956
LamictalTablet, chewable25 mg/1OralGlaxosmithkline Inc1998-09-03Not applicableUs00173 0527 00 nlmimage10 b518daa6
LamictalKitGlaxosmithkline Inc2003-09-29Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-lamotrigineTablet25 mgOralApotex Corporation2002-03-18Not applicableCanada
Apo-lamotrigineTablet100 mgOralApotex Corporation2002-03-18Not applicableCanada
Apo-lamotrigineTablet150 mgOralApotex Corporation2002-03-18Not applicableCanada
Auro-lamotrigineTablet150 mgOralAuro Pharma Inc2012-06-13Not applicableCanada
Auro-lamotrigineTablet100 mgOralAuro Pharma Inc2012-06-13Not applicableCanada
Auro-lamotrigineTablet25 mgOralAuro Pharma Inc2012-06-13Not applicableCanada
Dom-lamotrigineTablet150 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-lamotrigineTablet100 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-lamotrigineTablet25 mgOralDominion PharmacalNot applicableNot applicableCanada
LamotrigineTablet25 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-03-09Not applicableUs
International/Other Brands
Convulsan (Actavis) / Crisomet (Juste) / Dafex (Phoenix) / Daksol (Pharmavita) / Danoptin (Pliva) / Dezepil (Rafarm) / Elmendos (GlaxoSmithKline) / Epilepax (Ivax) / Epimil (Ivax) / Epiral (Zentiva) / Epitec (Cipla Medpro) / Epitrigine (Actavis) / Labileno (GlaxoSmithKline) / Lambipol (GlaxoSmithKline) / Lamect (PharmaSwiss) / Lameptil (Sandoz) / Lameptil S (Sandoz) / Lametec (Vitalchem) / Lamez (Intas) / Lamictal / Lamictal CD (GlaxoSmithKline) / Lamictin (GlaxoSmithKline) / Lamotrix (Glenmark) / Larig (Rowex) / Medotrigin (Medochemie) / Mogine (Douglas) / Trimolep (Psicofarma) / Trogine (Ranbaxy) / Xebarin (Dr Reddys)
Categories
UNII
U3H27498KS
CAS number
84057-84-1
Weight
Average: 256.091
Monoisotopic: 255.007850663
Chemical Formula
C9H7Cl2N5
InChI Key
PYZRQGJRPPTADH-UHFFFAOYSA-N
InChI
InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)
IUPAC Name
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
SMILES
NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1

Pharmacology

Indication

Indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures/primary generalized tonic-clonic seizures/generalized seizures of Lennox-Gastaut syndrome [FDA Label].

Indicated for conversion to monotherapy in adults (≥16 years of age) with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED)[FDA Label].

Indicated for the maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (≥18 years of age) treated for acute mood episodes with standard therapy [FDA Label].

Structured Indications
Pharmacodynamics

Lamotrigine, an antiepileptic drug (AED) of the phenyltriazine class, is chemically unrelated to existing antiepileptic drugs. Lamotrigine displays a broader therapeutic profile than earilier antiepileptic drugs with significant efficacy against absence seizures [7]. Lamotrigine is thought to exert its anticonvulsant effect by stabilizing presynaptic neuronal membranes. Lamotrigine inhibits sodium currents by selectively binding to the inactivated state of the sodium channel and subsequently suppresses the release of the excilatory amino acid, glutamate. The mechanism of action of lamotrigine in reducing anticonvulsant activity is assumed to be the same for reducing biopolar depression. Lamotrigine demonstrates effectiveness in preventing the recurrence of mania and depression [7].

Lamotrigine binds to melanin-containing tissues such as eyes and pigmented skin [FDA Label]. The metabolite of lamotrigine formed by glucuronidation, 2-N-methyl metabolite, is reported to cause dose-dependent prolongations of the PR interval, widening of the QRS complex, and, at higher doses, complete AV conduction block. Although the metabolite is only found in trace amounts in humans, the plasma concentrations of this metabolite may be increased in conditions where the extent of glucuronidation is reduced, such as liver disease [FDA Label].

Mechanism of action

Although chemically unrelated, lamotrigine resembles the actions of phenytoin and carbamazepine in inhibiting voltage-sensitive sodium channes thereby stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory amino acids such as glutamate and aspartate [FDA Label]. Studies on lamotrigine show binding to sodium channels similar to local anesthetics, which could explain potential clinical benefit of lamotrigine in some neuropathic pain states [7].

Lamotrigine displays binding properties to several different receptors. It mediates a weak inhibitory effect on serotonin 5-HT3 receptor with IC50 of 18 µM [FDA Label]. It also weakly binds to Adenosine A1/A2 receptors, α1/α2/β adrenergic receptors, dopamine D1/D2 receptors, GABA A/B receptors, histamine H1 receptors, κ-opioid receptor (KOR), mACh receptors and serotonin 5-HT2 receptors with an IC50>100 µM [FDA Label]. Lamotrigine had weak effects at sigma opioid receptors (IC50 = 145 µM) [FDA Label]. A study demonstrated an evidence in vivo that lamotrigine inhibits Cav2.3 (R-type) calcium currents that could also contribute to its anticonvulsant activity [6]. This inhibition of calcium currents is also observed in topiramate.

TargetActionsOrganism
AVoltage-dependent R-type calcium channel subunit alpha-1E
inhibitor
Human
USodium channel protein type 2 subunit alpha
inhibitor
Human
UAdenosine receptor A1
inhibitor
Human
UAdenosine receptor A2a
inhibitor
Human
UAlpha-1A adrenergic receptor
inhibitor
Human
UAlpha-2A adrenergic receptor
inhibitor
Human
UBeta-1 adrenergic receptor
inhibitor
Human
UD(1) dopamine receptor
inhibitor
Human
UD(2) dopamine receptor
inhibitor
Human
UGABA-A receptor (anion channel)
inhibitor
Human
UGABA-A receptor (benzodiazepine site)
inhibitor
Human
UHistamine H1 receptor
inhibitor
Human
UKappa-type opioid receptor
inhibitor
Human
UMuscarinic acetylcholine receptor
inhibitor
Human
U5-hydroxytryptamine receptor 2A
inhibitor
Human
U5-hydroxytryptamine receptor 3A
inhibitor
Human
Absorption

Lamotrigine is rapidly and completely absorbed with negligible first-pass metabolism. Its oral absolute bioavailability is 98% which is not affected by food intake. Peak plasma concentrations is reached anywhere from 1.4 to 4.8 hours following drug administration, which varies depending on the dosing regimen of lamotrigine, concomitant medications, and epileptic states [FDA Label].

Volume of distribution

The mean apparent volume of distribution (Vd/F) of lamotrigine following oral administration ranges from 0.9 to 1.3 L/kg and is independent of dose administered [FDA Label]. Lamotrigine accumulated in the kidney of the male rat, which is atttributable to α-2 microglobulin [FDA Label].

Protein binding

The fraction of plasma protein is 55% in vitro. Lamotrigine is not expected to undergo clinically significant interactions with other drugs through competition for protein binding sites [FDA Label].

Metabolism

Lamotrigine predominantly undergoes glucuronidation to form 2-N-glucuronide conjugate, which is pharmacologically inactive. Of total radioactivity detected in urine following oral administration of 240 mg lamotrigine, the components recovered consisted of unchanged lamotrigine (10%), the 2-N-glucuronide (76%), a 5-N-glucuronide (10%), a 2-N-methyl metabolite (0.14%), and other unidentified minor metabolites (4%) [FDA Label].

Route of elimination

Following oral administration of 240 mg radiolabelled lamotrigine, about 94% of total drug and its metabolites administered is recovered in the urine and 2% is recovered in the feces [FDA Label].

Half life

The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.

Clearance

The mean apparent plasma clearance (Cl/F) ranges from 0.18 to 1.21 mL/min/kg. The values vary depending on dosing regimen, concomitant antiepileptic medications, and disease state of the individual [FDA Label].

Toxicity

Some fatal cases of overdose involving quantities up to 15 g have been reported. Overdose has resulted in ataxia, nystagmus, increased seizures, decreased level of consciousness, coma, and intraventricular conduction delay. While there is no known antidote for lamotrigine, hospitalization and general supportive care is recommended in case of suspected overdose. If indicated, gastric lavage and emesis may be required with appropriate precautions made to protect the airway. It is uncertain whether hemodialysis is an effective means of removing lamotrigine from the blood [FDA Label].

Oral TDLO in man is 19 mg/kg and oral TDLO (intermittent) in woman is 2 mg/kg/30H [MSDS]. Oral LD50 in mouse and rat is 205 mg/kg and 245 mg/kg, respectively [MSDS]. In animal studies, lamotrigine was not found to be teratogenic. However it decreased fetal folate concentrations in rats, an effect known to be associated with teratogenesis in animals and humans [FDA Label]. There is no evidence of carcinogenic or mutagenic potential for lamotrigine and effect of lamotrigine on human fertility is unknown [FDA Label].

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Lamotrigine.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Lamotrigine.Vet Approved
7-NitroindazoleThe risk or severity of adverse effects can be increased when Lamotrigine is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Lamotrigine.Approved, Illicit
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Lamotrigine.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lamotrigine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Lamotrigine.Approved
AmobarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Lamotrigine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Lamotrigine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Amperozide.Experimental
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Lamotrigine.Approved, Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Lamotrigine.Approved, Investigational
ApalutamideThe serum concentration of Lamotrigine can be decreased when it is combined with Apalutamide.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lamotrigine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Lamotrigine.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Lamotrigine.Approved
ArticaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Lamotrigine.Approved
AtazanavirThe serum concentration of Lamotrigine can be decreased when it is combined with Atazanavir.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Azaperone.Investigational, Vet Approved
AzelastineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Lamotrigine.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Lamotrigine.Experimental
BarbexacloneThe serum concentration of Lamotrigine can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Benzocaine.Approved, Investigational
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Lamotrigine.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Benzyl alcohol.Approved
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Lamotrigine.Approved, Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Lamotrigine.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lamotrigine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Lamotrigine.Investigational
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Lamotrigine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Bupivacaine.Approved, Investigational
BuprenorphineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Lamotrigine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lamotrigine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Lamotrigine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Butamben.Approved, Withdrawn
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Lamotrigine.Approved
ButethalThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Butethal.Approved, Illicit
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Lamotrigine.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lamotrigine.Approved, Illicit, Vet Approved
Calcium AcetateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Lamotrigine.Withdrawn
CanertinibThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Canertinib.Investigational
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Lamotrigine.Experimental
CarbamazepineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Lamotrigine.Approved
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Lamotrigine.Approved, Investigational
CaseinThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Lamotrigine.Approved
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Lamotrigine.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Lamotrigine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lamotrigine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chloroprocaine.Approved
ChlorotrianiseneThe serum concentration of Lamotrigine can be decreased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Lamotrigine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lamotrigine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Lamotrigine.Approved
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Lamotrigine.Approved, Investigational
CimetidineThe serum concentration of Lamotrigine can be increased when it is combined with Cimetidine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Lamotrigine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Lamotrigine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Lamotrigine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clopenthixol.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lamotrigine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lamotrigine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clothiapine.Experimental
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Lamotrigine.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Lamotrigine.Approved
CocaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Lamotrigine.Approved, Illicit
Conjugated estrogensThe serum concentration of Lamotrigine can be decreased when it is combined with Conjugated estrogens.Approved
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Lamotrigine.Investigational
CyclizineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lamotrigine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Cyclopropane.Experimental
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Lamotrigine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Lamotrigine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Lamotrigine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desmopressin.Approved
DesogestrelDesogestrel may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lamotrigine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Lamotrigine.Approved, Illicit, Investigational, Vet Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Lamotrigine.Vet Approved
DienestrolThe serum concentration of Lamotrigine can be decreased when it is combined with Dienestrol.Approved, Investigational
DienogestDienogest may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Diethyl ether.Experimental
DiethylstilbestrolThe serum concentration of Lamotrigine can be decreased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lamotrigine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lamotrigine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lamotrigine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dixyrazine.Experimental
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Lamotrigine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Lamotrigine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Doxepin.Approved, Investigational
DoxofyllineThe serum concentration of Doxofylline can be decreased when it is combined with Lamotrigine.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Lamotrigine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Vet Approved
DrospirenoneDrospirenone may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ecgonine.Experimental, Illicit
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Lamotrigine.Approved
EcopipamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Lamotrigine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Lamotrigine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Lamotrigine.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Lamotrigine.Approved, Illicit
EstradiolThe serum concentration of Lamotrigine can be decreased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Lamotrigine can be decreased when it is combined with Estramustine.Approved, Investigational
Estrogens, esterifiedThe serum concentration of Lamotrigine can be decreased when it is combined with Estrogens, esterified.Approved
Estrone sulfateThe serum concentration of Lamotrigine can be decreased when it is combined with Estrone sulfate.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lamotrigine.Approved, Investigational
EthanolLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Lamotrigine can be decreased when it is combined with Ethinyl Estradiol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethylmorphine.Approved, Illicit
Ethynodiol diacetateEthynodiol diacetate may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Etomidate.Approved
EtonogestrelEtonogestrel may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe serum concentration of Lamotrigine can be decreased when it is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lamotrigine.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Lamotrigine.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fexofenadine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluanisone.Experimental
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Lamotrigine.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Lamotrigine.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Lamotrigine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Lamotrigine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Lamotrigine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluticasone propionate.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Lamotrigine.Experimental
FluvoxamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe serum concentration of Lamotrigine can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lamotrigine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Lamotrigine.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Gepirone.Investigational
GestodeneGestodene may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Glutethimide.Approved, Illicit
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Lamotrigine.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Lamotrigine.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Guanfacine.Approved, Investigational
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Lamotrigine.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Lamotrigine.Approved
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Lamotrigine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Heroin.Approved, Illicit, Investigational
HexestrolThe serum concentration of Lamotrigine can be decreased when it is combined with Hexestrol.Withdrawn
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Lamotrigine.Approved, Investigational
HexobarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Hexobarbital.Approved
HydrocodoneLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lamotrigine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Lamotrigine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Indiplon.Investigational
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Lamotrigine.Withdrawn
IsavuconazoleThe serum concentration of Lamotrigine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Lamotrigine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Lamotrigine.Approved, Vet Approved
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Lamotrigine.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Lamotrigine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Lamotrigine.Approved, Investigational
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Lamotrigine.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levomilnacipran.Approved, Investigational
LevonorgestrelLevonorgestrel may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lamotrigine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Lamotrigine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Lamotrigine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Lamotrigine.Approved
LumacaftorThe serum concentration of Lamotrigine can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Lamotrigine.Approved, Investigational
LynestrenolLynestrenol may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Lamotrigine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Lamotrigine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Lamotrigine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe therapeutic efficacy of Lamotrigine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Maprotiline.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Medetomidine.Vet Approved
Medroxyprogesterone acetateMedroxyprogesterone acetate may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
MefloquineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Melperone.Approved, Investigational
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Lamotrigine.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lamotrigine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Mesoridazine.Approved, Investigational
MestranolThe serum concentration of Lamotrigine can be decreased when it is combined with Mestranol.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Metaxalone.Approved
MetforminThe serum concentration of Metformin can be increased when it is combined with Lamotrigine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Lamotrigine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methadyl Acetate.Approved, Illicit
MethallenestrilThe serum concentration of Lamotrigine can be decreased when it is combined with Methallenestril.Experimental
MethapyrileneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Lamotrigine.Approved, Vet Approved
MethohexitalThe serum concentration of Lamotrigine can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methylecgonine.Experimental
MethylphenobarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Methylphenobarbital.Approved
MetyrosineLamotrigine may increase the sedative activities of Metyrosine.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Lamotrigine.Experimental
MianserinThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Mianserin.Approved, Investigational
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Lamotrigine.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Lamotrigine.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Lamotrigine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Milnacipran.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Lamotrigine.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
MirtazapineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Molindone.Approved
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Lamotrigine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Lamotrigine.Approved, Investigational
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Lamotrigine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
NafcillinThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Lamotrigine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lamotrigine.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Lamotrigine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Nefazodone.Approved, Withdrawn
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Lamotrigine.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Lamotrigine.Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Lamotrigine.Approved
NitroprussideLamotrigine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Lamotrigine.Approved, Vet Approved
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Lamotrigine.Approved
NorelgestrominNorelgestromin may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
NorfluraneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Norflurane.Approved, Investigational
NorgestimateNorgestimate may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
NorgestrelNorgestrel may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Lamotrigine.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Lamotrigine.Approved, Vet Approved
OlanzapineThe serum concentration of Lamotrigine can be decreased when it is combined with Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Olopatadine.Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Lamotrigine.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Lamotrigine can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lamotrigine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Oxethazaine.Approved, Investigational
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Lamotrigine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lamotrigine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lamotrigine.Approved, Investigational, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Lamotrigine.Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lamotrigine.Approved
ParaldehydeLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Penfluridol.Experimental
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Lamotrigine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lamotrigine.Approved, Vet Approved
PentobarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved
PerazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Lamotrigine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Lamotrigine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Phenibut.Experimental
PhenobarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Lamotrigine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Lamotrigine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Piritramide.Approved, Investigational
PitolisantThe serum concentration of Lamotrigine can be decreased when it is combined with Pitolisant.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pomalidomide.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Lamotrigine.Approved, Investigational, Vet Approved
PramipexoleLamotrigine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Lamotrigine.Approved
PregabalinThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Prilocaine.Approved
PrimidoneThe serum concentration of Lamotrigine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideThe serum concentration of Procainamide can be increased when it is combined with Lamotrigine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lamotrigine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Lamotrigine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Lamotrigine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Lamotrigine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Lamotrigine is combined with PSD502.Investigational
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Lamotrigine.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Lamotrigine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lamotrigine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Raclopride.Investigational
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Lamotrigine.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ramelteon.Approved, Investigational
RanolazineThe serum concentration of Lamotrigine can be increased when it is combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lamotrigine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Lamotrigine.Approved, Investigational
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Lamotrigine.Approved, Investigational
RifampicinThe metabolism of Lamotrigine can be increased when combined with Rifampicin.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Lamotrigine.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Lamotrigine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Lamotrigine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Lamotrigine can be decreased when it is combined with Ritonavir.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Romifidine.Vet Approved
RopiniroleLamotrigine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ropivacaine.Approved
RotigotineLamotrigine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Lamotrigine.Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Lamotrigine.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Lamotrigine.Approved, Investigational, Vet Approved
ScopolamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Scopolamine.Approved, Investigational
SecobarbitalThe serum concentration of Lamotrigine can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Sepranolone.Investigational
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Lamotrigine.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lamotrigine.Approved, Vet Approved
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Lamotrigine.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Lamotrigine.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Lamotrigine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lamotrigine.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Lamotrigine.Approved
SulpirideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Sultopride.Experimental
SuvorexantLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Lamotrigine can be decreased when it is combined with Synthetic Conjugated Estrogens, A.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Lamotrigine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tasimelteon.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Lamotrigine.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Lamotrigine.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Lamotrigine.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Lamotrigine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Lamotrigine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tetrodotoxin.Investigational
ThalidomideLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe serum concentration of Lamotrigine can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe serum concentration of Lamotrigine can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Lamotrigine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lamotrigine.Approved
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Lamotrigine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tilidine.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Lamotrigine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tizanidine.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Lamotrigine.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Lamotrigine.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Lamotrigine.Approved, Investigational, Vet Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Lamotrigine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Lamotrigine.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Lamotrigine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lamotrigine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Triflupromazine.Approved, Vet Approved
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Lamotrigine.Experimental
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Lamotrigine.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Lamotrigine.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Lamotrigine.Investigational
Valproic AcidValproic Acid may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
VemurafenibThe serum concentration of Lamotrigine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Vinyl ether.Experimental
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Lamotrigine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lamotrigine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Lamotrigine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Zolazepam.Vet Approved
ZolpidemLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Lamotrigine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lamotrigine.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Grahame Roy Lee, "Process for the preparation of lamotrigine." U.S. Patent US5925755, issued January, 1981.

US5925755
General References
  1. Backonja M: Neuromodulating drugs for the symptomatic treatment of neuropathic pain. Curr Pain Headache Rep. 2004 Jun;8(3):212-6. [PubMed:15115640]
  2. Barbosa L, Berk M, Vorster M: A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003 Apr;64(4):403-7. [PubMed:12716240]
  3. Jensen TS: Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain. 2002;6 Suppl A:61-8. [PubMed:11888243]
  4. Pappagallo M: Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther. 2003 Oct;25(10):2506-38. [PubMed:14667954]
  5. Tehrani SP, Daryaafzoon M, Bakhtiarian A, Ejtemaeemehr S, Sahraei H: The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9. [PubMed:19579915]
  6. Dibue-Adjei M, Kamp MA, Alpdogan S, Tevoufouet EE, Neiss WF, Hescheler J, Schneider T: Cav2.3 (R-Type) Calcium Channels are Critical for Mediating Anticonvulsive and Neuroprotective Properties of Lamotrigine In Vivo. Cell Physiol Biochem. 2017;44(3):935-947. doi: 10.1159/000485361. Epub 2017 Nov 24. [PubMed:29176325]
  7. 44. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 544, 549). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
External Links
Human Metabolome Database
HMDB0014695
KEGG Drug
D00354
PubChem Compound
3878
PubChem Substance
46505408
ChemSpider
3741
BindingDB
50031299
ChEBI
6367
ChEMBL
CHEMBL741
Therapeutic Targets Database
DAP000039
PharmGKB
PA450164
IUPHAR
2622
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Lamotrigine
ATC Codes
N03AX09 — Lamotrigine
AHFS Codes
  • 28:12.92 — Miscellaneous Anticonvulsants
FDA label
Download (1.12 MB)
MSDS
Download (24.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingBasic SciencePsychiatric Disorder NOS1
1CompletedNot AvailableHealthy Volunteers8
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentBipolar Disorder (BD)1
1CompletedTreatmentBipolar Disorder (BD) / Epilepsies1
1CompletedTreatmentEpilepsies6
1CompletedTreatmentEpilepsies / Seizure, Absence1
1CompletedTreatmentFasting State1
1CompletedTreatmentFed1
1CompletedTreatmentHealthy Volunteers8
1CompletedTreatmentHealthy Volunteers / Psychiatric Disorder NOS2
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1RecruitingTreatmentBipolar Affective Disorders / Bipolar Disorder (BD)1
1TerminatedTreatmentBipolar Disorder (BD) / Healthy Volunteers1
1, 2CompletedDiagnosticBipolar Disorder (BD) / Depression, Bipolar / Epilepsies / Seizures1
1, 2RecruitingTreatmentBrain Injury1
2CompletedTreatmentAnxiety Disorders / Moods Disorders / Psychotic Disorder NOS1
2CompletedTreatmentBipolar Disorder (BD)1
2CompletedTreatmentBipolar II Disorder, Most Recent Episode Major Depressive1
2CompletedTreatmentCocaine-Related Disorders1
2CompletedTreatmentDermatillomania / Neurotic Excoriation / Pathologic Skin Picking / Psychogenic Excoriation1
2CompletedTreatmentEpilepsies2
2CompletedTreatmentMixed Mania Bipolar Disorder1
2CompletedTreatmentNeurotic Disorders / Obsessive-Compulsive Disorder (OCD)1
2CompletedTreatmentSecondary Progressive Multiple Sclerosis (SPMS)1
2RecruitingTreatmentNoonan Syndrome, Neurofibromatosis Type 11
2TerminatedTreatmentBipolar 1 Disorder1
2Unknown StatusTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
2WithdrawnTreatmentOpioid-Related Disorders1
2, 3CompletedTreatmentAddictions1
2, 3CompletedTreatmentTrigeminal Neuralgia (TN)1
2, 3RecruitingTreatmentNeurofibromatosis Type 11
3Active Not RecruitingTreatmentAdverse Effects / Epilepsy, Localization Related1
3CompletedNot AvailableSeizures1
3CompletedDiagnosticBipolar Disorder (BD)1
3CompletedSupportive CareNeurotoxicity / Pain / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentBinge Eating Disorder (BED) / BMI >30 kg/m21
3CompletedTreatmentBipolar Disorder (BD)7
3CompletedTreatmentBipolar Disorder (BD) / Depression, Bipolar2
3CompletedTreatmentChildhood Absence Epilepsy / Epilepsies / Petit Mal Epilepsy / Seizures1
3CompletedTreatmentDepression1
3CompletedTreatmentDepression, Bipolar1
3CompletedTreatmentDystrophia Myotonica Type 1 / Myotonia Congenita / Paralysis, Hyperkalemic Periodic / Paramyotonia Congenita / Potassium-Aggravated Myotonia1
3CompletedTreatmentEpilepsies6
3CompletedTreatmentEpilepsy, Localization Related2
3CompletedTreatmentMenière's Disease / Ménière's Vertigo / Vertigo, Aural / Vertigo, Intermittent1
3CompletedTreatmentMoods Disorders1
3CompletedTreatmentSchizophrenic Disorders2
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentBipolar Disorder (BD)1
3TerminatedTreatmentEpilepsies1
3WithdrawnTreatmentAlcohol Dependence / Post Traumatic Stress Disorder (PTSD)1
4Active Not RecruitingTreatmentBipolar Disorder (BD) / Depression / Depression, Bipolar / Lamotrigine / Melancholic Depression1
4CompletedNot AvailableHippocampal Atrophy Due to Corticosteroid / Hypomania Due to Corticosteroid Use / Memory Impairment Due to Corticosteroid Use1
4CompletedBasic ScienceEpilepsies1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedHealth Services ResearchMemory Disturbances1
4CompletedPreventionBipolar Disorder (BD)1
4CompletedTreatmentBipolar Disorder (BD)7
4CompletedTreatmentBipolar Disorder (BD) / Dependence, Cocaine1
4CompletedTreatmentBipolar Disorder (BD) / Depression1
4CompletedTreatmentBipolar Disorder (BD) / Mania1
4CompletedTreatmentBipolar I Disorder / Bipolar II Disorder1
4CompletedTreatmentBorderline Personality Disorder (BPD)1
4CompletedTreatmentBronchial Asthma1
4CompletedTreatmentEpilepsies5
4CompletedTreatmentEpilepsy, Localization Related2
4CompletedTreatmentEpilepsy, Tonic-Clonic1
4CompletedTreatmentMajor Depressive Disorder (MDD)1
4Enrolling by InvitationTreatmentEpilepsies1
4Not Yet RecruitingBasic ScienceBariatric Surgery Candidate1
4Not Yet RecruitingBasic ScienceEpilepsies1
4RecruitingNot AvailableEpilepsies1
4RecruitingTreatmentBipolar Disorder (BD)1
4RecruitingTreatmentEpilepsies1
4TerminatedTreatmentMajor Depressive Disorder (MDD)1
4Unknown StatusTreatmentAlcohol Dependence / Bipolar Disorder (BD) / Depression / Mania / Psychosis1
4Unknown StatusTreatmentEpilepsies1
Not AvailableAvailableNot AvailableAcute and Chronic Pain Following Modified Radical Mastectomy1
Not AvailableCompletedNot AvailableBipolar Disorder (BD)3
Not AvailableCompletedNot AvailableEpilepsies4
Not AvailableCompletedBasic ScienceDepression, Bipolar1
Not AvailableCompletedPreventionBipolar Disorder (BD) / Depression / Psychotic Disorder NOS / Schizophrenic Disorders1
Not AvailableCompletedTreatmentBipolar Disorder (BD)1
Not AvailableCompletedTreatmentFacial Neuropathy1
Not AvailableCompletedTreatmentTrigeminal Neuralgia (TN)1
Not AvailableCompletedTreatmentUnipolar Depression1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableDepression / Suicidal Ideation1
Not AvailableRecruitingNot AvailableEpilepsies1
Not AvailableRecruitingNot AvailableObesity, Morbid1
Not AvailableRecruitingBasic ScienceBipolar Disorder (BD) / Depression, Bipolar / Unipolar Depression1
Not AvailableTerminatedTreatmentAdolescent Depression1
Not AvailableUnknown StatusTreatmentAdults With Tonic Clonic Seizures and/or Partial Seizures1
Not AvailableUnknown StatusTreatmentEpilepsies1

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Aurobindo pharma ltd
  • Dr reddys laboratories ltd
  • Glenmark generics ltd
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Taro pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • Smithkline beecham corp
  • Smithkline beecham corp dba glaxosmithkline
  • Apotex inc
  • Cadista pharmaceuticals inc
  • Lupin ltd
  • Matrix laboratories ltd
  • Roxane laboratories inc
  • Torrent pharmaceuticals ltd
  • Upsher smith laboratories inc
  • Wockhardt ltd
Packagers
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • Atlantic Biologicals Corporation
  • Aurobindo Pharma Ltd.
  • Cadila Healthcare Ltd.
  • Cadista Pharmaceuticals Inc.
  • Cardinal Health
  • Caremark LLC
  • Cobalt Pharmaceuticals Inc.
  • Compass Pharma Services LLC
  • Comprehensive Consultant Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • DSM Corp.
  • GlaxoSmithKline Inc.
  • Glenmark Generics Ltd.
  • Greenstone LLC
  • Heartland Repack Services LLC
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Mckesson Corp.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pharmacy Service Center
  • Physicians Total Care Inc.
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sandoz
  • Stat Rx Usa
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals
  • UDL Laboratories
  • Vangard Labs Inc.
  • Zydus Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral150 mg/1
TabletOral150 mg
TabletOral2 mg
TabletOral25 mg
TabletOral5 mg
Tablet, chewableOral2 mg/1
TabletOral200 mg
Tablet, orally disintegratingOral100 mg/1
Tablet, orally disintegratingOral200 mg/1
Tablet, orally disintegratingOral25 mg/1
Tablet, orally disintegratingOral50 mg/1
Tablet, film coated, extended releaseOral100 mg/1
Tablet, film coated, extended releaseOral200 mg/1
Tablet, film coated, extended releaseOral25 mg/1
Tablet, film coated, extended releaseOral250 mg/1
Tablet, film coated, extended releaseOral300 mg/1
Tablet, film coated, extended releaseOral50 mg/1
Kit
TabletOral100 mg/1
TabletOral200 mg/1
TabletOral25 mg/1
TabletOral250 mg/1
TabletOral50 mg/1
Tablet, chewableOral25 mg/1
Tablet, chewableOral5 mg/1
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral200 mg/1
Tablet, extended releaseOral25 mg/1
Tablet, extended releaseOral300 mg/1
Tablet, extended releaseOral50 mg/1
Tablet, for suspensionOral25 mg/1
Tablet, for suspensionOral5 mg/1
TabletOral300 mg/1
Prices
Unit descriptionCostUnit
LaMICtal Starter 98 25 (84)-100(14)mg Kit Box556.69USD box
LaMICtal XR 200 mg 24 Hour tablet12.11USD tablet
Lamictal xr 200 mg tablet11.65USD tablet
LaMICtal XR 100 mg 24 Hour tablet11.36USD tablet
Lamictal xr 100 mg tablet10.92USD tablet
Lamictal xr 50 mg tablet10.2USD tablet
Lamictal 200 mg tablet7.44USD tablet
Lamictal odt start kt (orange)7.28USD tablet
Lamictal xr start kit (orange)7.28USD tablet
Lamictal odt 200 mg tablet6.95USD tablet
Lamictal odt 100 mg tablet5.82USD tablet
Lamotrigine 200 mg tablet5.78USD tablet
LaMICtal 25 mg Chew Tabs5.63USD tab
Lamictal odt 50 mg tablet5.46USD tablet
Lamictal tab start kit (green)5.46USD tablet
Lamictal 150 mg tablet5.38USD tablet
Lamictal odt 25 mg tablet5.1USD tablet
Lamictal xr 25 mg tablet5.1USD tablet
Lamictal 100 mg tablet4.72USD tablet
Lamotrigine tablet starter kit4.24USD tablet
Lamotrigine 150 mg tablet3.98USD tablet
Lamictal 25 mg tablet3.78USD tablet
Lamotrigine 100 mg tablet3.52USD tablet
LamoTRIgine 25 mg Chew Tabs3.33USD tab
LamoTRIgine 5 mg Chew Tabs3.18USD tab
Lamotrigine 25 mg tablet2.9USD tablet
Apo-Lamotrigine 150 mg Tablet1.31USD tablet
Mylan-Lamotrigine 150 mg Tablet1.31USD tablet
Novo-Lamotrigine 150 mg Tablet1.31USD tablet
Pms-Lamotrigine 150 mg Tablet1.31USD tablet
Ratio-Lamotrigine 150 mg Tablet1.31USD tablet
Apo-Lamotrigine 100 mg Tablet0.88USD tablet
Mylan-Lamotrigine 100 mg Tablet0.88USD tablet
Novo-Lamotrigine 100 mg Tablet0.88USD tablet
Pms-Lamotrigine 100 mg Tablet0.88USD tablet
Ratio-Lamotrigine 100 mg Tablet0.88USD tablet
Apo-Lamotrigine 25 mg Tablet0.22USD tablet
Mylan-Lamotrigine 25 mg Tablet0.22USD tablet
Novo-Lamotrigine 25 mg Tablet0.22USD tablet
Pms-Lamotrigine 25 mg Tablet0.22USD tablet
Ratio-Lamotrigine 25 mg Tablet0.22USD tablet
Lamictal 5 mg Chewable Tablet0.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5698226No1995-07-292012-07-29Us
CA2277722No2001-03-272012-01-29Canada
US9144547No2003-09-222023-09-22Us
US8637512No2008-06-142028-06-14Us
US8840925No2008-07-022028-07-02Us
US7919115No2009-01-042029-01-04Us
US9339504No2008-07-022028-07-02Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)216-218 °C (uncorr)Not Available
logP2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.488 mg/mLALOGPS
logP1.87ALOGPS
logP1.93ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)14.98ChemAxon
pKa (Strongest Basic)5.87ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area90.71 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity66.62 m3·mol-1ChemAxon
Polarizability23.1 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9382
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.7155
P-glycoprotein inhibitor INon-inhibitor0.911
P-glycoprotein inhibitor IINon-inhibitor0.9604
Renal organic cation transporterNon-inhibitor0.8176
CYP450 2C9 substrateNon-substrate0.9162
CYP450 2D6 substrateNon-substrate0.9055
CYP450 3A4 substrateNon-substrate0.6862
CYP450 1A2 substrateNon-inhibitor0.611
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.7007
CYP450 2C19 inhibitorNon-inhibitor0.8594
CYP450 3A4 inhibitorNon-inhibitor0.7678
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5515
Ames testNon AMES toxic0.8202
CarcinogenicityNon-carcinogens0.7895
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7556 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9168
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0090000000-0ca7be847ef73a25032b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0c09-0890000000-f7244245bf6816d03dc7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-97d10d3ad5d45edcaeba
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-b2dbf89c13423bc1b59f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-d26cb5886894916aa1d8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0590000000-528845465e0a140f6b60
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0930000000-9a68c83a3573a48cf6c2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0kmi-0900000000-bb97e1aecda1747cbf29
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-97d10d3ad5d45edcaeba
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-97d10d3ad5d45edcaeba
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0090000000-1e756e80b9a7d4b0dd18
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0490000000-a29a09ef58e19c7e62e1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0940000000-85279d67921a0106c4e2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0kmi-0900000000-eba38744d927d1c39a74
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ab9-0790000000-036c53ed1835e3d33348
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0290000000-26664a56093e292ec551
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0190000000-33187897c9fb0b0a178f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-2940000000-1a4f3a098b426ac4febb

Taxonomy

Description
This compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Dichlorobenzenes
Alternative Parents
Aminotriazines / Imidolactams / Aryl chlorides / 1,2,4-triazines / Heteroaromatic compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
1,2-dichlorobenzene / Aminotriazine / Aryl chloride / Aryl halide / Triazine / Imidolactam / 1,2,4-triazine / Heteroaromatic compound / Organoheterocyclic compound / Azacycle
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
dichlorobenzene, primary arylamine, 1,2,4-triazines (CHEBI:6367)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1E gives rise to R-type calcium currents. R-type calcium channels belong to the 'high-voltage activated' (HVA) group and are blocked by nickel, and partially by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to dihydropyridines (DHP), omega-conotoxin-GVIA (omega-CTx-GVIA), and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing alpha-1E subunit could be involved in the modulation of firing patterns of neurons which is important for information processing.
Specific Function
Calcium channel activity
Gene Name
CACNA1E
Uniprot ID
Q15878
Uniprot Name
Voltage-dependent R-type calcium channel subunit alpha-1E
Molecular Weight
261729.05 Da
References
  1. Dibue-Adjei M, Kamp MA, Alpdogan S, Tevoufouet EE, Neiss WF, Hescheler J, Schneider T: Cav2.3 (R-Type) Calcium Channels are Critical for Mediating Anticonvulsive and Neuroprotective Properties of Lamotrigine In Vivo. Cell Physiol Biochem. 2017;44(3):935-947. doi: 10.1159/000485361. Epub 2017 Nov 24. [PubMed:29176325]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN2A
Uniprot ID
Q99250
Uniprot Name
Sodium channel protein type 2 subunit alpha
Molecular Weight
227972.64 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Lipkind GM, Fozzard HA: Molecular modeling of local anesthetic drug binding by voltage-gated sodium channels. Mol Pharmacol. 2005 Dec;68(6):1611-22. Epub 2005 Sep 20. [PubMed:16174788]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Purine nucleoside binding
Specific Function
Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
ADORA1
Uniprot ID
P30542
Uniprot Name
Adenosine receptor A1
Molecular Weight
36511.325 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
Gene Name
ADORA2A
Uniprot ID
P29274
Uniprot Name
Adenosine receptor A2a
Molecular Weight
44706.925 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.

Components:
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...

Components:
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...

Components:
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein homodimerization activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A4
Uniprot ID
P22310
Uniprot Name
UDP-glucuronosyltransferase 1-4
Molecular Weight
60024.535 Da
References
  1. Argikar UA, Senekeo-Effenberger K, Larson EE, Tukey RH, Remmel RP: Studies on induction of lamotrigine metabolism in transgenic UGT1 mice. Xenobiotica. 2009 Nov;39(11):826-35. doi: 10.3109/00498250903188985. [PubMed:19845433]
  2. Chen H, Yang K, Choi S, Fischer JH, Jeong H: Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. Drug Metab Dispos. 2009 Sep;37(9):1841-7. doi: 10.1124/dmd.109.026609. Epub 2009 Jun 22. [PubMed:19546240]
  3. Argikar UA, Remmel RP: Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 2009 May;39(5):355-63. doi: 10.1080/00498250902745082. [PubMed:19387891]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
References
  1. Argikar UA, Remmel RP: Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 2009 May;39(5):355-63. doi: 10.1080/00498250902745082. [PubMed:19387891]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Nadph binding
Specific Function
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA pre...
Gene Name
DHFR
Uniprot ID
P00374
Uniprot Name
Dihydrofolate reductase
Molecular Weight
21452.61 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Luna-Tortos C, Fedrowitz M, Loscher W: Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008 Dec;55(8):1364-75. doi: 10.1016/j.neuropharm.2008.08.032. Epub 2008 Sep 11. [PubMed:18824002]

Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 23:01